Stockscreener 앱 받기
30.57
1.12%
0.34
시장 영업 전:
30.85
0.28
+0.92%
전일 마감가:
$30.23
열려 있는:
$30.24
하루 거래량:
1.17M
Relative Volume:
0.95
시가총액:
$2.89B
수익:
$225.27M
순이익/손실:
$-140.06M
주가수익비율:
-19.14
EPS:
-1.5974
순현금흐름:
$-87.93M
1주 성능:
+8.91%
1개월 성능:
+8.37%
6개월 성능:
-9.58%
1년 성능:
+36.53%
1일 변동 폭
$29.68
$30.85
1주일 범위
$26.81
$30.85
52주 변동 폭
$20.50
$39.28
Ideaya Biosciences Inc Stock (IDYA) Company Profile
명칭
Ideaya Biosciences Inc
전화
650-443-6209
주소
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
30.57 | 2.86B | 225.27M | -140.06M | -87.93M | -1.5974 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-09-18 | 개시 | Guggenheim | Buy |
| 2025-09-04 | 개시 | Barclays | Overweight |
| 2025-09-04 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-07-22 | 개시 | TD Cowen | Buy |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-06-26 | 개시 | Wells Fargo | Overweight |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-11-05 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-07-08 | 개시 | Mizuho | Outperform |
| 2024-03-08 | 개시 | BTIG Research | Buy |
| 2023-08-08 | 개시 | SVB Securities | Outperform |
| 2023-05-24 | 개시 | Goldman | Buy |
| 2023-04-24 | 업그레이드 | Stifel | Hold → Buy |
| 2023-03-23 | 개시 | Berenberg | Buy |
| 2023-02-28 | 개시 | RBC Capital Mkts | Outperform |
| 2022-12-28 | 개시 | CapitalOne | Overweight |
| 2022-10-27 | 개시 | Citigroup | Buy |
| 2022-08-15 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2022-03-10 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-23 | 개시 | Stifel | Hold |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-03-11 | 개시 | Guggenheim | Buy |
| 2020-10-07 | 개시 | Wedbush | Outperform |
| 2020-09-01 | 개시 | Northland Capital | Outperform |
| 2020-07-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-06-17 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-06 | 개시 | H.C. Wainwright | Buy |
| 2020-03-13 | 개시 | ROTH Capital | Buy |
| 2019-10-17 | 개시 | Oppenheimer | Outperform |
| 2019-09-10 | 개시 | Robert W. Baird | Outperform |
| 2019-06-17 | 개시 | Citigroup | Buy |
| 2019-06-17 | 개시 | JP Morgan | Neutral |
| 2019-06-17 | 개시 | Jefferies | Buy |
모두보기
Ideaya Biosciences Inc 주식(IDYA)의 최신 뉴스
Responsive Playbooks and the IDYA Inflection - Stock Traders Daily
IDEAYA Biosciences enrolls first patient in IDE892 Phase 1/2 trial - grafa.com
Why is Ideaya Biosciences stock rallying today? By Investing.com - Investing.com Canada
Ideaya Biosciences stock rises on phase 1/2 cancer trial start By Investing.com - Investing.com South Africa
Ideaya begins trial of IDE892 combo in lung, pancreatic cancer - Investing.com
IDEAYA Biosciences, Inc. (IDYA) Latest Stock News & Headlines - Yahoo Finance
New drug combo targets MTAP-deleted pancreatic and lung cancers - Stock Titan
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GuruFocus
Wedbush Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $58 - Moomoo
IDEAYA Biosciences, Inc. (IDYA) reports Q1 loss, misses revenue estimates - MSN
IDEAYA files shelf offering to raise up to $300M - MSN
Ideaya Biosciences (IDYA) Forms Clinical Partnership With Roche for IDE892 Efficacy Study - Insider Monkey
IDEAYA Biosciences: 'Strong Buy' On Darovasertib NDA Filing Submission Completion H2 2026 - Seeking Alpha
Ideaya Biosciences Stock Crashes 10% Despite Citizens Reiterating Highly Bullish Price Target on Oncology Pipeline - TIKR.com
IDEAYA Biosciences prices $300M public offering of shares and pre-funded warrants at $27/share - MSN
IDEAYA Announces Closing of Public Offering Including Full Exerc - GuruFocus
IDEAYA Biosciences closes $345M public offering By Investing.com - Investing.com South Africa
IDEAYA Biosciences closes $345M public offering - Investing.com
IDEAYA Biosciences raises $323.6M in follow-on offering of common stock and pre-funded warrants - TradingView
IDEAYA Biosciences (NASDAQ: IDYA) raises $323.6M via stock and pre-funded warrants - Stock Titan
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - PR Newswire
5 Best AI Driven Biotech Stocks to Invest In - Insider Monkey
IDEAYA (NASDAQ: IDYA) raises ~$281M via 5.56M shares and pre-funded warrants - Stock Titan
UBS Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Update: IDEAYA Shares Fall After Pricing $300 Million Offering - Moomoo
Peninsula company lines up $345 million stock deal targeting eye cancer - The Business Journals
Mission Produce Posts Downbeat Q2 Earnings, Joins Ideaya Biosciences, Perrigo And Other Big Stocks Moving - Benzinga
Ideaya: Expect Offering to Close on or About June 10 >IDYA - Moomoo
Citizens reiterates Ideaya Biosciences stock rating on ASCO data By Investing.com - Investing.com Canada
IDEAYA Biosciences prices $300 million stock offering By Investing.com - Investing.com Australia
IDEAYA Biosciences prices $300 million stock offering - Investing.com UK
IDEAYA sets $27 price in $300M stock and warrant sale to investors - Stock Titan
IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants - Financial Times
IDEAYA Announces Proposed Public Offering of Common Stock and Pr - GuruFocus
Ideaya Biosciences stock falls on $300M stock offering plan By Investing.com - Investing.com Australia
IDEAYA Biosciences plans $300 million stock offering By Investing.com - Investing.com Australia
Ideaya Biosciences stock falls on $300M stock offering plan - Investing.com India
IDEAYA Biosciences plans $300 million stock offering - Investing.com
IDEAYA (NASDAQ: IDYA) seeks $300M in stock and pre-funded warrants, $45M option - Stock Titan
IDEAYA Biosciences plans up to $300M stock, warrant sale, plus $45M option - Stock Titan
What IDEAYA Biosciences (IDYA)'s Darovasertib Phase 2/3 Win and Roche Deal Mean For Shareholders - Yahoo Finance
IDEAYA (IDYA) Chief Development Officer reports 297,200-share stock option holding - Stock Titan
Understanding the Setup: (IDYA) and Scalable Risk - Stock Traders Daily
Ideaya Biosciences Inc (IDYA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.27%
1.43%
자본화:
|
볼륨(24시간):